By InvitationNot Applicable

CAMELLIA Cohort: A Longitudinal Study to Understand Sexual Health and Prevention Among Women in Alabama

United States830 participantsStarted 2023-12-12

Plain-language summary

Pre-exposure prophylaxis (PrEP) is an important biomedical human immunodeficiency virus (HIV) prevention tool and may particularly benefit black, cis and trans-gender women, who are at an increased risk for HIV and Sexually Transmitted Infections (STIs). The purpose of this study is to use a population-based approach to create a cohort of cis and trans-gender women at risk for future HIV acquisition to better understand the factors associated with the risk of STIs and HIV diagnosis and predictors of PrEP use.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Self identify as a Cis-gender or Trans-gender woman * Age 18 - 89 * Reported STI in past 3 months by the Alabama Department of Public Health (ADPH) * Gonorrhea and Syphilis negative * HIV negative at screening encounter * Live in Alabama * Have access to a private smart phone Exclusion Criteria: * Live outside of Alabama * Positive diagnosis for HIV, Gonorrhea, or Syphilis

What they're measuring

Annualized Sexually Transmitted Infections (STIs)

Timeframe: From time of enrollment through study completion at 24 months

Trial details

NCT IDNCT05463692

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-30

View on ClinicalTrials.gov More Hiv trials